Ariad Pharmaceuticals

Sharp price increases for cancer drugs
Sharp price increases for cancer drugsA majority of oncology drugs—particularly older cancer drugs—had price hikes in 2015, according to a study. Plus, Ariad Pharmaceuticals raised the price of its chronic myeloid leukemia (CML) drug ponatinib (Iclusig) for the fourth time this year to around $199,000 a year, according to The Street.
Sales of leukemia chemotherapy drug suspendedCiting the risk of life-threatening blood clots and severe narrowing of blood vessels, FDA has asked Ariad Pharmaceuticals to suspend marketing and sales of ponatinib (Iclusig).
Sales of leukemia chemotherapy drug suspendedCiting the risk of life-threatening blood clots and severe narrowing of blood vessels, FDA has asked Ariad Pharmaceuticals to suspend marketing and sales of ponatinib (Iclusig).
Ponatinib: An oral tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemiaPonatinib (Iclusig; Ariad Pharmaceuticals) is an oral tyrosine kinase inhibitor (TKI) that was approved by FDA on December 14, 2012, for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myelogenous leukemia (CML) that is resistant or intolerant to previous TKI therapy, and for Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (Ph+ALL).